Boehringer Ingelheim and Microsoft announced an early-stage collaboration to develop AI-based “digital patient twins” intended to simulate disease progression and treatment response for clinical trial use. The partners plan to evaluate whether these models can help improve trial design and support synthetic or hybrid control approaches, potentially reducing control-group patient numbers. The companies framed the initiative as exploratory and subject to robust scientific validation and regulatory approvals. The work is positioned within a broader push toward AI-assisted clinical development, with the US HHS SURPASS program also using digital patient twins for multiple trial-design tasks. For biotech stakeholders, the immediate impact is methodological: if validated, digital twins could influence endpoints planning, feasibility assessments, and comparator selection—though any deployment will hinge on evidence standards and regulator comfort with model-based inference.